Intramuscular aripiprazole or haloperidol and transition to oral therapy in patients with agitation associated with schizophrenia: sub-analysis of a double-blind study
Authors:
- 21 September 2006
- journal article
- research article
- Published by Informa Healthcare in Current Medical Research and Opinion
- Vol. 22 (11) , 2209-2219
Abstract
Objective: A sub-population analysis of 325 patients with agitation (Positive and Negative Syndrome Scale Excited Component [PEC] score ≥ 15 and ≤ 32; score of ≥ 4 on ≥ 2 items) associated with schizophrenia in a randomized, double-blind study investigating the efficacy and tolerability of intramuscular (IM) aripiprazole 9.75 mg, IM haloperidol 6.5 mg, or IM placebo and the transition to oral therapy.Research design and methods: Over 24 h, patients could receive up to three IM injections; the second and third administered ≥ 2 and ≥ 4 h, respectively, after the first, if deemed clinically necessary. Following IM treatment, oral aripiprazole or haloperidol was administered for 4 days. The primary efficacy measure was the mean change in PEC score from baseline at 2 h.Results: At 2 h, mean improvements in PEC scores with IM aripiprazole (–8.0) were significantly greater versus IM placebo (–5.7; p ≤ 0.01), and similar versus IM haloperidol (–8.3). Secondary efficacy measures also significantly improved...Keywords
This publication has 16 references indexed in Scilit:
- Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double-blind, placebo-controlled comparison with intramuscular haloperidolPsychopharmacology, 2006
- Evidence for Onset of Antipsychotic Effects Within the First 24 Hours of TreatmentAmerican Journal of Psychiatry, 2005
- Ziprasidone and haloperidol in the treatment of acute exacerbation of schizophrenia and schizoaffective disorder: comparison of intramuscular and oral formulations in a 6-week, randomized, blinded-assessment studyPsychopharmacology, 2005
- Pharmacological Management of Acute AgitationDrugs, 2005
- Aripiprazole for the Prevention of Relapse in Stabilized Patients With Chronic SchizophreniaThe Journal of Clinical Psychiatry, 2003
- Aripiprazole, an Antipsychotic With a Novel Mechanism of Action, and Risperidone vs Placebo in Patients With Schizophrenia and Schizoaffective DisorderArchives of General Psychiatry, 2003
- A comparison of the efficacy and safety of olanzapine versus haloperidol during transition from intramuscular to oral therapyClinical Therapeutics, 2003
- Efficacy and Safety of Aripiprazole and Haloperidol Versus Placebo in Patients With Schizophrenia and Schizoaffective DisorderThe Journal of Clinical Psychiatry, 2002
- A Double-blind, Placebo-Controlled Dose-Response Comparison of Intramuscular Olanzapine and Haloperidol in the Treatment of Acute Agitation in SchizophreniaArchives of General Psychiatry, 2002
- Emergency Psychiatry: Contemporary Practices in Managing Acutely Violent Patients in 20 Psychiatric Emergency RoomsPsychiatric Services, 1999